Literature DB >> 20404514

Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten(+/-) preclinical mouse model.

Sarada Vissapragada1, Anup Ghosh, Lymor Ringer, Patricia Salinas, Amanda Brophy, Daniel Peaceman, Bhaskar Kallakury, Partha P Banerjee, Stanley T Fricke, William Helfrich, Yi Chien Lee, Richard Pestell, Philipp Scherer, Herbert B Tanowitz, Maria Laura Avantaggiati, Leena Hilakivi-Clarke, Michael P Lisanti, Olga C Rodriguez, Chris Albanese.   

Abstract

Diet and obesity, and their associated metabolic alterations, are some of the fastest-growing causes of disease and death in America. Findings from epidemiological studies correlating obesity, the sources of dietary fat and prostate cancer (PCa) are conflicting. We have previously shown that 15% of PB-ErbB-2 x pten(+/-) mice developed PCa and exhibited increased phosphorylated 4E-BP1, but not the key PI3-kinase intermediary phospho-protein, mTOR, when maintained on unrefined mouse chow. We report herein that 100% of animals fed refined, westernized AIN-93-based diets containing corn oil developed PCa by 12 months of age. Increases in visceral fat and mTO R activation in the tumors were also observed. Furthermore, nuclear cyclin E levels were significantly induced by the AIN-93-corn oil-based diets versus chow. Replacing 50% of the corn oil with menhaden oil, with 21% of its triglycerides being n-3 PUFA's, had no effect on tumorigenesis, fat deposition, cyclin E or mTOR. Phosphorylated BAD levels were similar in the tumors of mice in all three diets. Our data demonstrated that in the context of our preclinical model, components of crude chow, but not dietary n-3 PUFAs, protect against PCa progression. In addition, these data establish phosphorylated mTOR, nuclear cyclin E and visceral fat deposits as possible biomarkers of increased dietary risk for PCa.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404514      PMCID: PMC3557519          DOI: 10.4161/cc.9.9.11542

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.

Authors:  Christopher J Kane; William W Bassett; Natalia Sadetsky; Stefanie Silva; Katrine Wallace; David J Pasta; Matthew R Cooperberg; June M Chan; Peter R Carroll
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  Body mass index as a predictor of prostate cancer: development versus detection on biopsy.

Authors:  Stephen J Freedland; Martha K Terris; Elizabeth A Platz; Joseph C Presti
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

3.  Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells.

Authors:  N F Guilbaud; N Gas; M A Dupont; A Valette
Journal:  J Cell Physiol       Date:  1990-10       Impact factor: 6.384

4.  Visceral fat accumulation as a risk factor for prostate cancer.

Authors:  Pedro von Hafe; Francisco Pina; Ana Pérez; Margarida Tavares; Henrique Barros
Journal:  Obes Res       Date:  2004-12

5.  In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models.

Authors:  Stanley T Fricke; Olga Rodriguez; John Vanmeter; Luis E Dettin; Mathew Casimiro; Christopher D Chien; Tionanatasha Newell; Kevin Johnson; Lilia Ileva; John Ojeifo; Michael D Johnson; Chris Albanese
Journal:  Prostate       Date:  2006-05-15       Impact factor: 4.104

6.  Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.

Authors:  Chad R Ritch; Robert L Wan; Leonard B Stephens; Jerome B Taxy; Dezheng Huo; Edward M Gong; Gregory P Zagaja; Charles B Brendler
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

7.  A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Authors:  Olga C Rodriguez; Edwin W Lai; Sarada Vissapragada; Caroline Cromelin; Maral Avetian; Patricia Salinas; Hida Ramos; Bhaskar Kallakury; Mathew Casimiro; Michael P Lisanti; Herbert B Tanowitz; Karel Pacak; Robert I Glazer; Maria Avantaggiati; Chris Albanese
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

8.  Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.

Authors:  Stephen J Freedland; Martha K Terris; Joseph C Presti; Christopher L Amling; Christopher J Kane; Bruce Trock; William J Aronson
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

9.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

10.  Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer.

Authors:  Michael F Leitzmann; Meir J Stampfer; Dominique S Michaud; Katarina Augustsson; Graham C Colditz; Walter C Willett; Edward L Giovannucci
Journal:  Am J Clin Nutr       Date:  2004-07       Impact factor: 7.045

View more
  9 in total

Review 1.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

2.  VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.

Authors:  Lymor Ringer; Paul Sirajuddin; Venkata Mahidhar Yenugonda; Anup Ghosh; Kyle Divito; Valerie Trabosh; Yesha Patel; Amanda Brophy; Scott Grindrod; Michael P Lisanti; Dean Rosenthal; Milton L Brown; Maria Laura Avantaggiati; Olga Rodriguez; Chris Albanese
Journal:  Cancer Biol Ther       Date:  2010-08-03       Impact factor: 4.742

3.  Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.

Authors:  Sungjin Kim; Xiangkun Yang; Amelia Yin; Junyi Zha; Zanna Beharry; Aiping Bai; Alicja Bielawska; Michael G Bartlett; Hang Yin; Houjian Cai
Journal:  Prostate       Date:  2019-03-22       Impact factor: 4.104

4.  Manganese-Enhanced Magnetic Resonance Imaging as a Diagnostic and Dispositional Tool after Mild-Moderate Blast Traumatic Brain Injury.

Authors:  Olga Rodriguez; Michele L Schaefer; Brock Wester; Yi-Chien Lee; Nathan Boggs; Howard A Conner; Andrew C Merkle; Stanley T Fricke; Chris Albanese; Vassilis E Koliatsos
Journal:  J Neurotrauma       Date:  2015-12-14       Impact factor: 5.269

5.  Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.

Authors:  Paula Vainio; Laura Lehtinen; Tuomas Mirtti; Mika Hilvo; Tuulikki Seppänen-Laakso; Johannes Virtanen; Anna Sankila; Stig Nordling; Johan Lundin; Antti Rannikko; Matej Orešič; Olli Kallioniemi; Kristiina Iljin
Journal:  Oncotarget       Date:  2011-12

6.  High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.

Authors:  Sung-Hyeok Hong; Jason U Tilan; Susana Galli; Ewa Izycka-Swieszewska; Taylor Polk; Meredith Horton; Akanksha Mahajan; David Christian; Shari Jenkins; Rachel Acree; Katherine Connors; Phuong Ledo; Congyi Lu; Yi-Chien Lee; Olga Rodriguez; Jeffrey A Toretsky; Chris Albanese; Joanna Kitlinska
Journal:  Oncotarget       Date:  2015-03-30

7.  Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma.

Authors:  Congyi Lu; Akanksha Mahajan; Sung-Hyeok Hong; Susana Galli; Shiya Zhu; Jason U Tilan; Nouran Abualsaud; Mina Adnani; Stacey Chung; Nada Elmansy; Jasmine Rodgers; Olga Rodriguez; Christopher Albanese; Hongkun Wang; Maureen Regan; Valerie Zgonc; Jan Blancato; Ewa Krawczyk; G Ian Gallicano; Michael Girgis; Amrita Cheema; Ewa Iżycka-Świeszewska; Luciane R Cavalli; Svetlana D Pack; Joanna Kitlinska
Journal:  Nat Commun       Date:  2022-04-28       Impact factor: 17.694

8.  A high-fat diet containing whole walnuts (Juglans regia) reduces tumour size and growth along with plasma insulin-like growth factor 1 in the transgenic adenocarcinoma of the mouse prostate model.

Authors:  Paul A Davis; Vihas T Vasu; Kishorchandra Gohil; Hyunsook Kim; Imran H Khan; Carroll E Cross; Wallace Yokoyama
Journal:  Br J Nutr       Date:  2012-01-16       Impact factor: 3.718

9.  Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.

Authors:  Paul Sirajuddin; Sudeep Das; Lymor Ringer; Olga C Rodriguez; Angiela Sivakumar; Yi-Chien Lee; Aykut Üren; Stanley T Fricke; Brian Rood; Alpay Ozcan; Sean S Wang; Sana Karam; Venkata Yenugonda; Patricia Salinas; Emanuel Petricoin; Michael Pishvaian; Michael P Lisanti; Yue Wang; Richard Schlegel; Bahram Moasser; Chris Albanese
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.